Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

BACKGROUND: Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active symptom control alone can improve survival and...

Full description

Bibliographic Details
Main Authors: Ford, Hugo, Marshall, Andrea, Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda, Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary, Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M., Dunn, Janet A.
Format: Article
Language:English
Published: Elsevier 2014
Online Access:http://eprints.nottingham.ac.uk/43067/
http://eprints.nottingham.ac.uk/43067/
http://eprints.nottingham.ac.uk/43067/
http://eprints.nottingham.ac.uk/43067/1/lancet_oncology_2014_2.pdf

Internet

http://eprints.nottingham.ac.uk/43067/
http://eprints.nottingham.ac.uk/43067/
http://eprints.nottingham.ac.uk/43067/
http://eprints.nottingham.ac.uk/43067/1/lancet_oncology_2014_2.pdf

Similar Items